⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNX News
Scienture Holdings, Inc. Common Stock
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
globenewswire.com
SCNX
Scienture Holdings, Inc. Announces Reverse Stock Split
globenewswire.com
SCNX
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX